Cleveland Clinic Researchers Identify Distinct Biomarkers for Predicting CAR T-Cell Therapy Response in B-Cell Lymphoma
核心洞察
Cleveland Clinic researchers have identified distinct baseline immune and plasma protein signatures that can predict response to different types of CAR T-cell therapy in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (搜索).
The study revealed that predictive biomarkers differ significantly between CAR T-cells engineered with 4-1BB (搜索) versus CD28 (搜索) costimulatory domains, with early memory T cells predicting response to 4-1BB-based therapy while central memory CD8+ T cells predict resistance to CD28-based therapy.
In a phase 1 trial of 26 patients receiving 4-1BB (搜索)-based CAR T-cells, 19 achieved complete remission at six months, with responders showing significantly higher frequencies of early memory T cells and type 2 functional T cells.
Cleveland Clinic researchers have made a significant breakthrough in personalizing CAR T-cell therapy for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (搜索) (NHL), identifying distinct biomarkers that can predict response to different types of chimeric antigen receptor T-cell treatments. The findings, presented at the American Society of Hematology meeting, could transform how clinicians select the most appropriate CAR T-cell therapy for individual patients.
Addressing the Challenge of Limited Response Rates
Although CD19 (搜索)-directed CAR T-cell therapy has revolutionized treatment for many blood cancers, fewer than 40% of patients experience long-term remission. While post-infusion parameters such as CAR T-cell persistence, certain phenotypes, tumor burden and the immune microenvironment correlate with efficacy, reliable baseline or pre-lymphodeletion biomarkers to predict clinical response have remained elusive.
"Until now, it was not clear that the reasons for failing or responding to CAR T-cell therapy differed between the different CAR T-cell types," says study co-investigator Paolo Caimi, MD, Associate Bone Marrow Transplant Director for Cellular Therapy at Cleveland Clinic. "Going forward, we hope to use that information to help better personalize the choice of treatment for a given patient."
Distinct Biomarkers for Different CAR T-Cell Products
The research revealed that baseline immune and plasma protein signatures can predict response and resistance to CAR T-cells engineered with 4-1BB (搜索), a signaling molecule that activates T-cells after binding to tumor cells. Importantly, these biomarkers differ substantially from predictors of response to CAR T-cells manufactured with CD28 (搜索), a different signaling molecule.
This distinction is clinically relevant because current commercially available CAR T-cell products for B-cell NHL use different activation molecules. Axicabtagene ciloleucel incorporates a CD28 (搜索) costimulatory domain, while tisagenlecleucel and lisocabtagenemaraleucel (搜索) are both engineered using a 4-1BB (搜索) costimulatory domain. CD28 provides stronger, faster activation leading to rapid proliferation but with slightly more toxicity, whereas 4-1BB is slower and provides longer-lasting, more resilient CAR T cells with lower toxicity.
Clinical Trial Results Reveal Key Predictive Factors
In a phase 1 clinical trial, 26 patients with relapsing/refractory B-cell NHL received CD19 (搜索) CAR T-cells manufactured using 4-1BB (搜索) costimulatory domains. The results were encouraging: 19 patients achieved complete remission at six months while three achieved partial remission.
The study identified several key predictive factors for response to 4-1BB (搜索)-based therapy. Responders showed significantly higher frequencies of early memory T cells, while non-responders had higher proportions of effector memory and terminal effector cells. Consistent with previous findings in B-cell acute lymphoblastic leukemia (搜索), T cells with type 2 function were significantly enriched in responders - marking the first such finding in NHL. Additionally, regulatory T cells were reduced in non-responders, and proteomic analysis identified baseline and post-infusion differences between responders and non-responders.
Contrasting Patterns in CD28-Based Therapy
A separate study involving 60 heavily pretreated patients with large B-cell lymphoma (搜索) who received axicabtagene ciloleucel revealed markedly different predictive patterns. At six months, the overall response rate was 56.7% and the complete response rate was 57.6%. However, one specific baseline central memory CD8+ T-cell signature strongly predicted resistance to CD28 (搜索)-based CAR T-cell therapy in NHL, contradicting prior assumptions that memory T cells are always beneficial in CAR T-cell therapy.
In non-responders to CD28 (搜索)-based therapy, pre-infusion CD8+ T cells showed type 2 polarization, thought to reflect tumor-driven adaptation that impairs cytotoxicity. This contrasts sharply with findings for 4-1BB (搜索)-based CAR T-cell products, where memory function and type 2 CAR T-cells are necessary for long-term efficacy and persistence.
Implications for Personalized Treatment
"The biomarkers could not be any more different between the two CAR T types," explains lead investigator J. Joseph Melenhorst, PhD, Director of Cell Therapy and Immuno-Engineering Program and Professor at Cleveland Clinic's Lerner College of Medicine. "We now believe that early identification of these phenotypes at leukapheresis may enable better patient stratification and guide use of alternative products to maximize therapeutic success."
The research also confirmed that particular T-cell subsets present in starting material are crucial for therapeutic outcomes. "It suggests that we can pre-select the cells that are predicted to drive the response. We can isolate those and make responses better," Dr. Melenhorst noted.
Future Directions
Under Dr. Melenhorst's leadership, Cleveland Clinic is establishing an in-house point-of-care manufacturing center for CAR T-cell therapy. The center has been approved to construct a Good Manufacturing Practice facility for developing and processing cellular products for future clinical trials. "Our next step is to use our findings to produce more effective CAR T-cells," Dr. Melenhorst says.
These findings represent a significant step toward truly personalized CAR T-cell therapy, potentially improving outcomes for patients with relapsed/refractory B-cell NHL by enabling clinicians to select the most appropriate CAR T-cell product based on individual patient biomarker profiles.